Transmedics Group Inc (NASDAQ: TMDX) stock jumped 2.92% on Friday to $68.70 against a previous-day closing price of $66.75. With 0.72 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.91 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $69.28 whereas the lowest price it dropped to was $66.76. The 52-week range on TMDX shows that it touched its highest point at $99.63 and its lowest point at $36.42 during that stretch. It currently has a 1-year price target of $79.20. Beta for the stock currently stands at 1.90.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of TMDX was up-trending over the past week, with a rise of 19.75%, but this was up by 66.99% over a month. Three-month performance surged to 5.21% while six-month performance fell -5.16%. The stock gained 19.92% in the past year, while it has gained 11.31% so far this year. A look at the trailing 12-month EPS for TMDX yields -1.10 with Next year EPS estimates of -0.40. For the next quarter, that number is -0.08. This implies an EPS growth rate of 25.43% for this year and 56.68% for next year.
Float and Shares Shorts:
At present, 32.14 million TMDX shares are outstanding with a float of 31.43 million shares on hand for trading. On Oct 30, 2023, short shares totaled 6.51 million, which was 19.94% higher than short shares on Sep 28, 2023. In addition to Dr. Waleed H. Hassanein M.D. as the firm’s Founder, President, CEO & Director, Mr. Stephen Gordon serves as its CFO, Treasurer & Secretary.
Other institutions hold 67.47% of TMDX, in contrast to 41.08% held by mutual funds. Shares owned by individuals account for 19.78%. As the largest shareholder in TMDX with 13.15% of the stake, Fidelity Management & Research Co holds 4,289,165 shares worth 4,289,165. A second-largest stockholder of TMDX, BlackRock Fund Advisors, holds 2,196,250 shares, controlling over 6.73% of the firm’s shares. The Vanguard Group, Inc. is the third largest shareholder in TMDX, holding 1,718,950 shares or 5.27% stake. With a 3.45% stake in TMDX, the Fidelity Advisor Series I -Growth is the largest stakeholder. A total of 1,124,817 shares are owned by the mutual fund manager. The CS Invt. Fds. 2 -, which owns about 3.28% of TMDX stock, is the second-largest Mutual Fund holder. It holds 1,070,000 shares valued at 40.1 million. Vanguard Total Stock Market ETF holds 3.00% of the stake in TMDX, owning 977,190 shares worth 36.63 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for TMDX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With TMDX analysts setting a high price target of $100.00 and a low target of $54.00, the average target price over the next 12 months is $79.20. Based on these targets, TMDX could surge 45.56% to reach the target high and fall by -21.4% to reach the target low. Reaching the average price target will result in a growth of 15.28% from current levels.
Summary of Insider Activity:
Insiders traded TMDX stock several times over the past three months with 4 Buys and 6 Sells. In these transactions, 12,980 shares were bought while 15,208 shares were sold. The number of buy transactions has increased to 59 while that of sell transactions has risen to 94 over the past year. The total number of shares bought during that period was 752,548 while 334,884 shares were sold.